Friday 6 November 2026 Export TMO’s income statement to Excel — free account

Thermo Fisher Scientific Inc.

TMO Healthcare Diagnostics & Research

Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024.

Revenue: +9.13%
EPS: +8.64%
Free cash flow: +15.0%
Total debt: +22.8%

Quarter to September 2026, against a year earlier

692.56 15.62 +2.31%

Follow TMO

Alert me

Market cap: $250.8B
P/E: 35.8×
Fwd P/E: 35.7×
Dividend yield: 0.27%
F-score: 5/9
Altman Z: 3.84
Beneish M: −2.46
Dividend safety: 88/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Thermo Fisher Scientific Inc. 10-Q filed Aug 1, 2025

Fiscal Q2 2025 · Period ended Jun 28, 2025 · Filed Aug 1, 2025 · accepted 10:41 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-Q filed May 2, 2025: 1 removed